e.adeyemi

TL2 · Ibadan

Contributes reviews on supplier material. Based in Ibadan.

Joined 2 January 2025 · last posted 2d

89Posts here

1Topics

1Solutions

440Likes received

695Likes given

20Badges

155Days visited

2kPosts read

Recent activity

Full stream

Revisiting: The best-written scientific paper you have read Replied, post #118 · Lounge › Off topic · 26 Jul 2026 · 1 like Practical answer on best-written scientific paper, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide…
Why the Start Here categories exist, and what they are not for Replied, post #7 · marked as the solution · Start Here › Welcome · 17 Jul 2026 · 7 likes Genuine question rather than a rhetorical one: has anyone here actually observed Start, as opposed to read about it? The thread is long and I cannot tell.
What is genuinely unknown about long-term amylin agonism Replied, post #43 · Compounds › Cagrilintide & amylin analogues · 16 Jul 2026 · 25 likes Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate…
Coming back to: Time to steady state after a dose increase Replied, post #101 · Pharmacology › Pharmacokinetics · 14 Jul 2026 · 23 likes Half-life determines how quickly concentration approaches steady state and does not determine what the steady-state concentration is. Dose and clearance determine that.…
Follow-up: The most useful thing you learned here that was not the answer you came for Replied, post #25 · Lounge › Off topic · 14 Jul 2026 · 8 likes That is the distinction I keep failing to hold on to. Written down now.
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #35 · Compounds › Secretagogues & GH axis · 11 Jul 2026 · 0 likes What a well-designed human trial of a secretagogue would look like: randomised, placebo-controlled, adequate sample size, IGF-1 as primary outcome, muscle and strength…
What a certificate commits its issuer to — the long version Replied, post #22 · Analytics › COA interpretation · 10 Jul 2026 · 0 likes A chromatogram supplied as a small image is legible for peak shape and not for baseline detail. That is enough to sanity-check an integration and not enough to…
Reading a home test result without over-claiming Replied, post #106 · Analytics › Home & field testing · 5 Jul 2026 · 7 likes On post #104 — agreed on the reasoning, with one qualification. Practical experience of reading a home test result, offered as one case with the conditions stated, not…
Muscle cramps: the ordinary causes before the exotic ones — a second dataset Replied, post #21 · Practice › Side effects · 30 Jun 2026 · 25 likes Narrowing post #18, because the general version has more than one answer. Fatigue: commonly reported, frequently multifactorial. It is worth asking whether other…
SURPASS-2 and the comparator dose question that will not go away — what changed since Replied, post #3 · Compounds › Tirzepatide · 25 Jun 2026 · 11 likes Adding the measurement that the opening post says would settle it. Injection-site reactions were reported at a low but non-zero rate across the trials. The practical…
Private prescribing in the UK: what is actually involved Replied, post #43 · Regional › UK & Ireland · 20 Jun 2026 · 11 likes I have no financial interest in anything named in this thread and I want to say so before I comment on private prescribing, because it is the sort of subject where it…
An 18-month record including the parts that went badly Replied, post #41 · Outcomes › Progress reports · 14 Jun 2026 · 10 likes Source for the 18-month record figure, since it was asked for. It is in the discussion rather than the abstract, which is why the version circulating is stronger than…